These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39278830)

  • 1. A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs.
    Reese R; Nanavath SR; Martin J; Travers JB; Rohan CA
    J Dermatolog Treat; 2024 Dec; 35(1):2402912. PubMed ID: 39278830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
    Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
    J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.
    Clarke K; Ainslie-Garcia M; Ferko N; Shastri K
    J Med Econ; 2024; 27(1):952-962. PubMed ID: 39015093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Geat D; Conti A; Dapavo P; Piaserico S; De Simone C; Bianchi L; Costanzo A; Malagoli P; Malara G; Micali G; Naldi L; Offidani A; Patrizi A; Prignano F; Parodi A; Rongioletti F; Calzavara-Pinton P; Girolomoni G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):591-598. PubMed ID: 32419534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biosimilars: opportunities and risks].
    Grieshaber-Bouyer R; Lorenz HM
    Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Dermatology - theory becomes reality.
    Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
    Nast A; Rosumeck S; Seidenschnur K
    J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
    Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
    Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.